ProCE Banner Activity

Pilot Study: Combined CD19- and BCMA-Targeted CAR T-Cells in Relapsed/Refractory Myeloma

Slideset Download
Conference Coverage
Combined infusion of CD19- and BCMA-specific CAR T-cells generally well tolerated and produces high remission rates in patients with relapsed/refractory multiple myeloma.

Released: December 14, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology